Abstract
The process of prokaryotic drug discovery has been a model of success for over fifty years, yet the number of exploited bacterial targets is a mere fraction, less than 0.1% of the potential targets (based on total number of bacterial genes identified by gene sequence projects). To better understand the potential for drug intervention, multiple paradigms have been established in the pharmaceutical industry, all with some semblance of commonality and uniqueness to provide proprietary positioning, yet no company has been successful to date in taking a ‘genomics approach’ to the finish line of having a genomics-based drug on the market. Within this overview, we provide a strategic overview of a sample process for the identification, validation and exploitation of novel antibacterial targets ascertained through a bioinformatics-based genomics drug discovery program.
Keywords: microbial genomics, antibiotic discovery, prokaryotic drug, genomics approach, genomics-based drug
Current Pharmaceutical Design
Title: Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs
Volume: 8 Issue: 13
Author(s): Thomas J. Dougherty, John F. Barrett and Michael J. Pucci
Affiliation:
Keywords: microbial genomics, antibiotic discovery, prokaryotic drug, genomics approach, genomics-based drug
Abstract: The process of prokaryotic drug discovery has been a model of success for over fifty years, yet the number of exploited bacterial targets is a mere fraction, less than 0.1% of the potential targets (based on total number of bacterial genes identified by gene sequence projects). To better understand the potential for drug intervention, multiple paradigms have been established in the pharmaceutical industry, all with some semblance of commonality and uniqueness to provide proprietary positioning, yet no company has been successful to date in taking a ‘genomics approach’ to the finish line of having a genomics-based drug on the market. Within this overview, we provide a strategic overview of a sample process for the identification, validation and exploitation of novel antibacterial targets ascertained through a bioinformatics-based genomics drug discovery program.
Export Options
About this article
Cite this article as:
Dougherty J. Thomas, Barrett F. John and Pucci J. Michael, Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs, Current Pharmaceutical Design 2002; 8 (13) . https://dx.doi.org/10.2174/1381612023394782
DOI https://dx.doi.org/10.2174/1381612023394782 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alternative Splicing and Tumor Progression
Current Genomics TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology Efficient Purification of rhG-CSF and its PEGylated Forms and Evaluation for In Vitro Activities
Protein & Peptide Letters Novel Insights for Multiple Sclerosis and Demyelinating Disorders with Apoptosis, Autophagy, FoxO, and mTOR
Current Neurovascular Research Partial QSAR Analysis of Some Selected Natural Inhibitors of FAAH Suggests a Working Hypothesis for the Development of Endocannabinoid- Based Drugs
Current Drug Targets - CNS & Neurological Disorders Opioid-modulating Peptides: Mechanisms of Action
Current Topics in Medicinal Chemistry Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism Ferulic Acid-Loaded Lipid Nanostructures as Drug Delivery Systems for Alzheimers Disease: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Depression and Vascular Disease: Conceptual Issues, Relationships and Clinical Implications
Vascular Disease Prevention (Discontinued) Exploration of N-arylpiperazine Binding Sites of D2 Dopaminergic Receptor
Mini-Reviews in Medicinal Chemistry Oral HPV Infection: Current Strategies for Prevention and Therapy
Current Pharmaceutical Design Do Substance P and the NK1 Receptor have a Role in Depression and Anxiety?
Current Pharmaceutical Design Novel Treatment Options of Binge Eating Disorder
Current Medicinal Chemistry Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Differential Susceptibility of Naive and Differentiated PC-12 Cells to Methylglyoxal-Induced Apoptosis: Influence of Cellular Redox
Current Neurovascular Research DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Effects of Antipsychotics on the BDNF in Schizophrenia
Current Medicinal Chemistry Insights into the Metal-catalyzed Alkyne Hydroarylation Reactions and Related Processes for the Synthesis of Coumarins
Current Organic Chemistry Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued)